Viridian Therapeutics, Inc.\DE (VRDN) intrinsic value & 10-year financials
Viridian Therapeutics, Inc.\DE (VRDN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 40.4% a year to $70.8M, with an average return on invested capital of 833.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $19.03
- Market cap
- $851.7M
- Revenue (FY2025)
- $70.8M
- Revenue growth (10-yr CAGR)
- 40.4%
- ROIC (10-yr avg)
- 833.0%
- Free cash flow (FY2025)
- -$276.9M
VRDN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $70.8M | -$342.6M | — | -$276.9M | -512.9% | -65.7% |
| FY2024 | $302.0K | -$269.9M | — | -$232.8M | -99018.2% | -56.5% |
| FY2023 | $314.0K | -$237.7M | -$5.31 | -$185.1M | -81035.0% | -78.5% |
| FY2022 | $1.8M | -$129.9M | -$4.05 | -$94.6M | -7579.2% | -66.3% |
| FY2021 | $3.0M | -$79.4M | -$6.66 | -$54.9M | -2690.8% | -54.2% |
| FY2020 | $1.1M | -$110.7M | -$31.13 | -$29.8M | -10512.4% | 7769.5% |
| FY2019 | $4.5M | -$41.9M | — | -$36.1M | -941.0% | -306.6% |
| FY2018 | $8.4M | -$32.7M | — | -$27.3M | -394.5% | -219.4% |
| FY2017 | $4.0M | -$26.5M | — | -$28.4M | -662.8% | -2480.1% |
| FY2016 | $3.3M | -$12.7M | — | -$7.2M | -374.8% | 3887.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Viridian Therapeutics, Inc.DE is a consistent compounder, expanding top-line revenue at 40.4% annually over the past decade.
Viridian Therapeutics, Inc.DE has historically struggled to out-earn its cost of capital, averaging just -23.5% ROIC.
Viridian Therapeutics, Inc.DE capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Viridian Therapeutics, Inc.DE is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-254.26 per share.